idarubicin has been researched along with Invasiveness, Neoplasm in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Z; Li, Y; Liu, S; Tian, C; Wang, Y; Yang, H; Yu, Y; Yuan, T; Zhang, Y; Zhao, H; Zhao, Z | 1 |
| Abe, T; Arihara, Y; Fujii, S; Fujita, M; Hirako, T; Jyomen, W; Kato, J; Kuroda, H; Maeda, M; Sakurai, T; Yamada, M | 1 |
| Cho, D; Kim, HJ; Kim, SH; Kim, TS; Lee, IK; Song, JH | 1 |
| Boulin, M; Cercueil, JP; Chauffert, B; Cherblanc, V; Favelier, S; Guiu, B; Hamza, S; Hillon, P; Krausé, D; Lepage, C | 1 |
| Casak, S; Chantada, G; Dávila, MT; Fandiño, A; Manzitti, J; Raslawski, E; Schvartzman, E | 1 |
| Amiot, L; Caulet-Maugendre, S; Diebold, J; Drénou, B; Fardel, O; Fauchet, R; Lamy, T; Le Prisé, PY; Sasportes, M | 1 |
1 review(s) available for idarubicin and Invasiveness, Neoplasm
| Article | Year |
|---|---|
[Acute promyelocytic leukemia presenting with central nervous system involvement at initial diagnosis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Central Nervous System Neoplasms; Cytarabine; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Invasiveness; Treatment Outcome; Tretinoin | 2013 |
1 trial(s) available for idarubicin and Invasiveness, Neoplasm
| Article | Year |
|---|---|
Results of a prospective study for the treatment of retinoblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Child; Child, Preschool; Cyclophosphamide; Etoposide; Eye Enucleation; Eye Neoplasms; Female; Humans; Idarubicin; Infant; Male; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Optic Nerve Neoplasms; Prospective Studies; Retinoblastoma; Risk Factors; Scleral Diseases; Survival Analysis; Treatment Outcome; Vincristine | 2004 |
4 other study(ies) available for idarubicin and Invasiveness, Neoplasm
| Article | Year |
|---|---|
Modified conditioning regimen with idarubicin followed by autologous hematopoietic stem cell transplantation for invasive B-cell non-Hodgkin's lymphoma patients.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease Management; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult | 2021 |
Enhanced invasiveness of drug-resistant acute myeloid leukemia cells through increased expression of matrix metalloproteinase-2.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzopyrans; Blast Crisis; Blotting, Western; Cytarabine; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Matrix Metalloproteinase 2; Middle Aged; Neoplasm Invasiveness; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Tumor Cells, Cultured; Young Adult | 2009 |
Lipiodol trans-arterial chemoembolization of hepatocellular carcinoma with idarubicin: first experience.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cohort Studies; Confidence Intervals; Disease-Free Survival; Ethiodized Oil; Female; Femoral Artery; Follow-Up Studies; Humans; Idarubicin; Infusions, Intra-Arterial; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prospective Studies; Risk Assessment; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
CD3- CD56+ non-Hodgkin's lymphomas with an aggressive behavior related to multidrug resistance.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bone Marrow Transplantation; CD3 Complex; CD56 Antigen; Cell Nucleus; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Fatal Outcome; Female; Femoral Neoplasms; Herpesvirus 4, Human; Humans; Idarubicin; Immunophenotyping; Killer Cells, Natural; Lymphoma, Large-Cell, Immunoblastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Male; Methylprednisolone; Neoplasm Invasiveness; Neoplasm Proteins; Neoplastic Stem Cells; Pelvic Neoplasms; Prednisone; Quinine; Vincristine | 1997 |